Di Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Di Xia has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Gerhard Leinenga
Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St Lucia Campus, Brisbane, QLD 4072, Australia
1 shared publication - Hannah R. Nicholas
School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia
1 shared publication - Jürgen Götz
Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, Australia
1 shared publication - Yee Lian Chew
Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 72
What Renders TAU Toxic
TAU is a microtubule-associated protein that under pathological conditions such as Alzheimer’s disease forms insoluble, filamentous aggregates. When twenty years after TAU’s discovery the first TAU transgenic mouse models were established, one declared goal that was achieved was the modelling of authentic TAU aggregate formation in the form of neurofibrillary tangles. However, as we review here, it has become increasingly clear that TAU causes damage much before these filamentous aggregates develop. In fact, because TAU is a scaffolding protein, increased levels and an altered subcellular localisation (due to an increased insolubility and impaired clearance) result in the interaction of TAU with cellular proteins with which it would otherwise either not interact or do so to a lesser degree, thereby impairing their physiological functions. We specifically discuss the non-axonal localization of TAU, the role phosphorylation has in TAU toxicity and how TAU impairs mitochondrial functions. A major emphasis is on what we have learned from the four available TAU knock-out models in mice, and the knock-out of the TAU/MAP2 homologue PTL-1 in worms. It has been proposed that in human pathological conditions such as Alzheimer’s disease, a rare toxic TAU species exists which needs to be specifically removed to abrogate TAU’s toxicity and restore neuronal functions. However, what is toxic in one context may not be in another, and simply reducing, but not fully abolishing TAU levels may be sufficient to abrogate TAU toxicity.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 72
Open AccessWhat Renders TAU Toxic
TAU is a microtubule-associated protein that under pathological conditions such as Alzheimer’s disease forms insoluble, filamentous aggregates. When twenty years after TAU’s discovery the first TAU transgenic mouse models were established, one declared goal that was achieved was the modelling of authentic TAU aggregate formation in the form of neurofibrillary tangles. However, as we review here, it has become increasingly clear that TAU causes damage much before these filamentous aggregates develop. In fact, because TAU is a scaffolding protein, increased levels and an altered subcellular localisation (due to an increased insolubility and impaired clearance) result in the interaction of TAU with cellular proteins with which it would otherwise either not interact or do so to a lesser degree, thereby impairing their physiological functions. We specifically discuss the non-axonal localization of TAU, the role phosphorylation has in TAU toxicity and how TAU impairs mitochondrial functions. A major emphasis is on what we have learned from the four available TAU knock-out models in mice, and the knock-out of the TAU/MAP2 homologue PTL-1 in worms. It has been proposed that in human pathological conditions such as Alzheimer’s disease, a rare toxic TAU species exists which needs to be specifically removed to abrogate TAU’s toxicity and restore neuronal functions. However, what is toxic in one context may not be in another, and simply reducing, but not fully abolishing TAU levels may be sufficient to abrogate TAU toxicity.